As in our study, most of the patients were receiving recommended traditional HF therapies, including angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers (95%) and a beta-blocker (90%) [12]. The gene discussed is ACE; the disease is hydrops fetalis.